Regular ArticleDo cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
References (0)
Cited by (83)
A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships
2022, European Journal of Medicinal ChemistryCitation Excerpt :As depicted in (Fig. 18), MDR is acquired due to the overexpression of drug transport proteins like P-gp [160] and ABCB1 [161] which are responsible for the expulsion of anti-cancer agents and become a major cause for failure of chemotherapy [162]. [163]. Recent studies showed that MDR-associated protein (MRP), lung resistant protein (LRP) [164] and mutation of DNA topoisomerase II lead to enhanced cell resistance to anti-cancer drugs [165] which are expressed by tumor cells as MDR [166]. [167]. Search for an effective substrate or antagonist for these drug transporter proteins is being carried out [168].
Cisplatin resistance and opportunities for precision medicine
2016, Pharmacological ResearchCitation Excerpt :MRP2, also known as cMOAT (canalicular multispecific organic anion transporter), is the most favored MRP transporter contributing to cisplatin resistance. Overexpression of MRP2 is found in a variety of cisplatin resistant cells lines [107–109]. The expression of MRP2 is induced by cisplatin as well [110].
The role of ABC transporters in ovarian cancer progression and chemoresistance
2015, Critical Reviews in Oncology/HematologyCitation Excerpt :ABCC2 (MRP-2), the canalicular multispecific organic anion transporter (cMOAT), is ∼190 kDa and has 49% AA identity with ABCC1 [191]. It is thought to have a physiological role as an organic anion pump in the liver and play a role in detoxification of alkylating agents in the apical epithelium of the liver and kidney [192,193]. ABCC2 positivity varies from 16% to 100% in ovarian cancer tissue cohorts [91,114,194,195] (Table 4).
Synthesis of some novel benzofuran-2-yl(4,5-dihyro-3,5-substituted diphenylpyrazol-1-yl) methanones and studies on the antiproliferative effects and reversal of multidrug resistance of human MDR1-gene transfected mouse lymphoma cells in vitro
2011, European Journal of Medicinal ChemistryCitation Excerpt :The multidrug resistance of cancer cells is often associated with the over expression of P-glycoprotein (P-gp). Recent studies showed that tumor cells expressing MDR-associated protein (MRP), lung resistant protein (LRP) and mutation of DNA topoisomerase II are likely to be MDR [4,5]. Although several mechanisms have been reported, MDR results mainly from the over expression of ATP-binding cassette (ABC) transporters, such as, ABCB1 (P-glycoprotein, P-gp), ABCC1–7 (multidrug resistant related protein 1–7, MRP1–7) and ABCG2 (breast cancer resistance protein, BCRP), which pump out a enormous number of chemically dissimilar anticancer agents.
Physiological, pharmacological and clinical features of the multidrug resistance protein 2
2005, Biomedicine and PharmacotherapyCitation Excerpt :MRP2 plays an important role in the membrane transport of various drugs, including organic anions and anticancer agents, particularly at the biliary pole of hepatocytes. By this way, MRP2 is thought to be one of the major membrane transporters involved in the pharmacokinetic profile of drugs [7–9]; in addition, it may be involved in anticancer drug resistance [10]. MRP2 also handles endogenous compounds and alteration of this physiological function can lead to clinical disorders [11].